FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206476> ?p ?o ?g. }

• W4387206476 endingPage "e105" @default.
• W4387206476 startingPage "e105" @default.
• W4387206476 abstract "Stereotactic radiosurgery (SRS) provides high rates of local control for small brain metastases with low rates of radionecrosis (RN). Larger targets are associated with increased risk of both local progression (LP) and RN. In this analysis, we hypothesized that dosimetric and clinical parameters predict for risk of LP and RN in SRS targets larger than two centimeters.We retrospectively reviewed patients with one or more targets with either an intact versus post-operative cavity larger than 2.0 cm treated with LINAC-based SRS between 2017 and 2022 at one institution. We assessed for association between patient, treatment, and disease variables with LP and RN. Variables assessed included tumor resection status, PDL1 positivity, target volume, maximum and minimum target dose, EQD2 and BED (a/b = 2 for necrosis and a/b = 10 for tumor control), as well as receipt of steroids, bevacizumab, or systemic therapy before or after SRS. Radionecrosis was determined by characteristic radiographic changes. Analyses were performed for the entire cohort and within subsets including by resection status and dose fractionation.A total of 178 lesions in 143 patients were included. Targets with volume diameters measuring at least 2 cm were used. Median follow-up was 2.3 years. Overall survival at 1 and 2 years was 56% and 32%, respectively. Most lesions (n = 119) were resected and treated with SRS post-operatively. The most common dose and fractionation schemes used were 30 Gy in 5 fractions (n = 89) and 27 Gy in 3 fractions (n = 63). For the entire cohort, the cumulative incidence of LP 1 and 2 years was 26% and 34%, respectively. The cumulative incidence of radiographic radionecrosis at 1 and 2 years was 12% and 17%, respectively. There was no difference in LP or RN between 27 Gy in 3 fractions versus 30 Gy in 5 fractions (p>0.5 for both). Median planning target volume (PTV) size was 18.5 cc for the 27 Gy in 3 fraction group compared to 21.9 cc in the 30 Gy in 5 fraction group. Minimum or maximum dose within the target was not associated with increased risk of LP or RN. Among patients receiving 27 Gy in 3 fractions, patients treated with resection followed by SRS had lower risk of LP compared to those treated with SRS alone (HR: 0.15, 95% CI: 0.03-0.64, p = 0.011). Among patients receiving 30 Gy in 5 fractions, patients who received corticosteroids prior to SRS had a lower risk of RN (HR: 0.14, 95% CI: 0.03-0.66, p = 0.013). For the entire cohort as well as within all subgroups, PD-L1≥1% was associated with increased risk of RN (p<0.001 for all).Selecting the optimal SRS dose fractionation and planning parameters to minimize both LP and RN remains a challenge for large targets. In this analysis, 27 Gy in 3 fractions appeared to provide equivalent LP and RN compared to 30 Gy in 5 fractions, and may be more convenient for patients. Patients with PD-L1≥1% with large brain targets treated with SRS may be at increased risk of RN; corticosteroid prophylaxis may be considered in this population." @default.
• W4387206476 created "2023-09-30" @default.
• W4387206476 creator A5013062647 @default.
• W4387206476 creator A5021301950 @default.
• W4387206476 creator A5032981380 @default.
• W4387206476 creator A5042333597 @default.
• W4387206476 creator A5044261087 @default.
• W4387206476 creator A5044593939 @default.
• W4387206476 creator A5045791621 @default.
• W4387206476 creator A5054901373 @default.
• W4387206476 creator A5059043543 @default.
• W4387206476 creator A5067520533 @default.
• W4387206476 creator A5071466700 @default.
• W4387206476 creator A5083513023 @default.
• W4387206476 creator A5088854603 @default.
• W4387206476 creator A5090825402 @default.
• W4387206476 date "2023-10-01" @default.
• W4387206476 modified "2023-10-17" @default.
• W4387206476 title "Stereotactic Radiosurgery (SRS) for Large Brain Metastases: Dosimetric and Clinical Predictors of Local Progression and Radionecrosis" @default.
• W4387206476 doi "https://doi.org/10.1016/j.ijrobp.2023.06.878" @default.
• W4387206476 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784635" @default.
• W4387206476 hasPublicationYear "2023" @default.
• W4387206476 type Work @default.
• W4387206476 citedByCount "0" @default.
• W4387206476 crossrefType "journal-article" @default.
• W4387206476 hasAuthorship W4387206476A5013062647 @default.
• W4387206476 hasAuthorship W4387206476A5021301950 @default.
• W4387206476 hasAuthorship W4387206476A5032981380 @default.
• W4387206476 hasAuthorship W4387206476A5042333597 @default.
• W4387206476 hasAuthorship W4387206476A5044261087 @default.
• W4387206476 hasAuthorship W4387206476A5044593939 @default.
• W4387206476 hasAuthorship W4387206476A5045791621 @default.
• W4387206476 hasAuthorship W4387206476A5054901373 @default.
• W4387206476 hasAuthorship W4387206476A5059043543 @default.
• W4387206476 hasAuthorship W4387206476A5067520533 @default.
• W4387206476 hasAuthorship W4387206476A5071466700 @default.
• W4387206476 hasAuthorship W4387206476A5083513023 @default.
• W4387206476 hasAuthorship W4387206476A5088854603 @default.
• W4387206476 hasAuthorship W4387206476A5090825402 @default.
• W4387206476 hasConcept C126322002 @default.
• W4387206476 hasConcept C126838900 @default.
• W4387206476 hasConcept C141071460 @default.
• W4387206476 hasConcept C155806632 @default.
• W4387206476 hasConcept C167135981 @default.
• W4387206476 hasConcept C2776694085 @default.
• W4387206476 hasConcept C2777802072 @default.
• W4387206476 hasConcept C2780387249 @default.
• W4387206476 hasConcept C2989005 @default.
• W4387206476 hasConcept C509974204 @default.
• W4387206476 hasConcept C71924100 @default.
• W4387206476 hasConcept C72563966 @default.
• W4387206476 hasConcept C88879693 @default.
• W4387206476 hasConceptScore W4387206476C126322002 @default.
• W4387206476 hasConceptScore W4387206476C126838900 @default.
• W4387206476 hasConceptScore W4387206476C141071460 @default.
• W4387206476 hasConceptScore W4387206476C155806632 @default.
• W4387206476 hasConceptScore W4387206476C167135981 @default.
• W4387206476 hasConceptScore W4387206476C2776694085 @default.
• W4387206476 hasConceptScore W4387206476C2777802072 @default.
• W4387206476 hasConceptScore W4387206476C2780387249 @default.
• W4387206476 hasConceptScore W4387206476C2989005 @default.
• W4387206476 hasConceptScore W4387206476C509974204 @default.
• W4387206476 hasConceptScore W4387206476C71924100 @default.
• W4387206476 hasConceptScore W4387206476C72563966 @default.
• W4387206476 hasConceptScore W4387206476C88879693 @default.
• W4387206476 hasIssue "2" @default.
• W4387206476 hasLocation W43872064761 @default.
• W4387206476 hasLocation W43872064762 @default.
• W4387206476 hasOpenAccess W4387206476 @default.
• W4387206476 hasPrimaryLocation W43872064761 @default.
• W4387206476 hasRelatedWork W1983863207 @default.
• W4387206476 hasRelatedWork W1994448744 @default.
• W4387206476 hasRelatedWork W2015902877 @default.
• W4387206476 hasRelatedWork W2093044092 @default.
• W4387206476 hasRelatedWork W2886982882 @default.
• W4387206476 hasRelatedWork W2903232234 @default.
• W4387206476 hasRelatedWork W3082730574 @default.
• W4387206476 hasRelatedWork W3214062064 @default.
• W4387206476 hasRelatedWork W4319265242 @default.
• W4387206476 hasRelatedWork W4387206995 @default.
• W4387206476 hasVolume "117" @default.
• W4387206476 isParatext "false" @default.
• W4387206476 isRetracted "false" @default.
• W4387206476 workType "article" @default.